ATE289819T1 - Gedächnissverbesserung durch verabreichung von delta-5-androsten-3-beta-ol-7,17-dion und 3-beta- estern desselben - Google Patents

Gedächnissverbesserung durch verabreichung von delta-5-androsten-3-beta-ol-7,17-dion und 3-beta- estern desselben

Info

Publication number
ATE289819T1
ATE289819T1 AT99954931T AT99954931T ATE289819T1 AT E289819 T1 ATE289819 T1 AT E289819T1 AT 99954931 T AT99954931 T AT 99954931T AT 99954931 T AT99954931 T AT 99954931T AT E289819 T1 ATE289819 T1 AT E289819T1
Authority
AT
Austria
Prior art keywords
beta
dione
delta
esters
androsten
Prior art date
Application number
AT99954931T
Other languages
German (de)
English (en)
Inventor
Henry A Lardy
Jennifer Y Shi
Original Assignee
Humanetics Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Humanetics Corp filed Critical Humanetics Corp
Application granted granted Critical
Publication of ATE289819T1 publication Critical patent/ATE289819T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A61K31/568—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstanes, e.g. testosterone
    • A61K31/5685—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstanes, e.g. testosterone having an oxo group in position 17, e.g. androsterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia

Landscapes

  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Organic Chemistry (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)
AT99954931T 1998-10-16 1999-10-13 Gedächnissverbesserung durch verabreichung von delta-5-androsten-3-beta-ol-7,17-dion und 3-beta- estern desselben ATE289819T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US09/174,235 US6153606A (en) 1998-10-16 1998-10-16 Memory enhancement by the administration of Δ5-androstene-3β-ol-7,17-dione and 3β esters thereof
PCT/US1999/024076 WO2000023080A1 (en) 1998-10-16 1999-10-13 IMPROVING MEMORY BY THE ADMINISTRATION OF Δ5-ANDROSTENE-3β-OL-7,17-DIONE AND 3β ESTERS THEREOF

Publications (1)

Publication Number Publication Date
ATE289819T1 true ATE289819T1 (de) 2005-03-15

Family

ID=22635389

Family Applications (1)

Application Number Title Priority Date Filing Date
AT99954931T ATE289819T1 (de) 1998-10-16 1999-10-13 Gedächnissverbesserung durch verabreichung von delta-5-androsten-3-beta-ol-7,17-dion und 3-beta- estern desselben

Country Status (7)

Country Link
US (2) US6153606A (enExample)
EP (1) EP1123100B1 (enExample)
JP (1) JP2002527481A (enExample)
AT (1) ATE289819T1 (enExample)
CA (1) CA2344677A1 (enExample)
DE (1) DE69923988T2 (enExample)
WO (1) WO2000023080A1 (enExample)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6153606A (en) * 1998-10-16 2000-11-28 Humanetics Corporation Memory enhancement by the administration of Δ5-androstene-3β-ol-7,17-dione and 3β esters thereof
US6667299B1 (en) * 2000-03-16 2003-12-23 Hollis-Eden Pharmaceuticals, Inc. Pharmaceutical compositions and treatment methods
US7553829B2 (en) * 2000-11-30 2009-06-30 Humanetics Corporation Treatment of chronic fatigue syndrome and fibromyalgia syndrome
US6399085B1 (en) 2001-03-05 2002-06-04 Humanetics Corporation Method of moisturizing the skin by the topical application of Δ5-androstene-3β-ol-7,17 dione and metabolizable precursors thereof
US6399084B1 (en) 2001-03-05 2002-06-04 Humanetics Corporation Method for diminishing wrinkles and fine lines of the skin by the topical application of Δ5-androstene-3β-ol-7, 17 dione and metabolizable precursors thereof
US6465446B1 (en) 2001-03-12 2002-10-15 John C. Dykstra Treatment of dermatitis by the topical application of Δ5-androstene-3β-ol-7,17 dione and metabolizable precursors thereof
US8084446B2 (en) * 2005-04-26 2011-12-27 Eric Marchewitz Use of DHEA derivatives for enhancing physical performance
ATE487488T1 (de) 2006-03-09 2010-11-15 Cambridge Entpr Ltd Neuartige antibiotische zusammensetzungen

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4791099A (en) * 1984-10-29 1988-12-13 Chaovanee Aroonsakul Method of treatment for central nervous system diseases such as Alzheimer's's disease
US4812447A (en) * 1985-10-22 1989-03-14 City Of Hope Method for the treatment of nervous system degeneration
US5424463A (en) * 1990-08-29 1995-06-13 Humanetics Corporation Δ5-androstenes useful for promoting weight maintenance or weight loss and treatment process
US5292730A (en) * 1990-08-29 1994-03-08 Humanetics Corporation Modulation of immune system with Δ5-androstenes
US5641766A (en) * 1990-08-29 1997-06-24 Humanetics Corporation UP-regulation of immune system with Δ 5-Androstenes
ATE227992T1 (de) * 1990-08-29 2002-12-15 Humanetics Corp Behandlungsverfahren zur förderung des gewichtsverlustes unter verwendung eines substituierten delta-5-androstens
US5807848A (en) * 1990-08-29 1998-09-15 Humanetics Corporation Use of dehydroepeiandrosterone-3-carboxylates to control body weight
US5707983A (en) * 1990-08-29 1998-01-13 Humanetics Corporation Treatment of alzheimer's disease and modulation of immune system with Δ5-androstenes
US5585371A (en) * 1990-08-29 1996-12-17 Humanetics Corporation Treatment of immune system with Δ5-androstenes
CA2148373A1 (en) * 1993-09-02 1995-03-09 Henry A. Lardy Delta 5-androstenes useful for promoting weight maintenance or weight loss and treatment process
US5420028A (en) * 1993-10-13 1995-05-30 Northeastern Ohio Universities Truncated human cholesterol 7α-hydroxylase, method of production and use thereof
GB9421093D0 (en) * 1994-10-19 1994-12-07 Univ Edinburgh Hippocampus-associated proteins, DNA sequences coding therefore and uses thereof
US5556847A (en) * 1994-10-27 1996-09-17 Duquesne University Of The Holy Ghost Methods of effecting memory enhancement mediated by steroid sulfatase inhibitors
CA2250874A1 (en) * 1996-04-09 1997-10-16 Btg International Limited Use of 7 alpha-substituted steroids to treat neuropsychiatric, immune or endocrine disorders
US6153606A (en) * 1998-10-16 2000-11-28 Humanetics Corporation Memory enhancement by the administration of Δ5-androstene-3β-ol-7,17-dione and 3β esters thereof

Also Published As

Publication number Publication date
JP2002527481A (ja) 2002-08-27
US6489313B1 (en) 2002-12-03
DE69923988D1 (de) 2005-04-07
EP1123100B1 (en) 2005-03-02
EP1123100A1 (en) 2001-08-16
EP1123100A4 (en) 2001-12-19
DE69923988T2 (de) 2006-04-06
WO2000023080A1 (en) 2000-04-27
US6153606A (en) 2000-11-28
CA2344677A1 (en) 2000-04-27

Similar Documents

Publication Publication Date Title
DE68928874D1 (de) Biozide Zusammensetzungen
ATE232396T1 (de) Oxydiertes thymosin beta 4
FI973828A0 (fi) Yhdisteitä ja koostumuksia aktiivisten aineiden annostelemiseksi
ATE87927T1 (de) Demethylavermectine und herstellung dazu.
TR200000740T2 (tr) Dişleri beyazlatmak için metod ve kompozisyonlar.
DK0902789T3 (da) Androstenderivater
ATE413179T1 (de) Therapeutische verwendungen von steroiden bei blutzellmangelzustaenden
IT230597Y1 (it) Cerniera ad un perno per mobili
BG106057A (en) Method of enhancing the efficacy of anti-tumour agents
DE68903243D1 (de) Spannungs-stromumsetzer mit mos-transistoren.
ATE289819T1 (de) Gedächnissverbesserung durch verabreichung von delta-5-androsten-3-beta-ol-7,17-dion und 3-beta- estern desselben
DE68909966D1 (de) Stabilisierte Strom- und Spannungsquellen.
DE69821498D1 (de) Verwendung von amifostin
BR0010708A (pt) Glicosìdeos androgênicos e atividade androgênica dos mesmos
BG101401A (bg) Състави за орално приложение с удължено освобождаване на цисаприд
DE58902899D1 (de) 2',3'-dideoxypurinnucleosid/purinnucleosid-phosphorylase-inhibitor kombinationstherapie und zusammensetzungen dafuer.
NL191913C (nl) Dubbel gediffundeerde mosfet cel.
DE3675876D1 (de) Appetit mildernde und gegen gastritis wirksame zusammensetzung.
DE60003943D1 (de) Trimegestone enthaltende pharmazeutische zusammensetzungen
DE69630527D1 (de) Vorbeugung einer krankheit mit diabetes charakter
MY106885A (en) Use of tenidap to reduce total serum cholesterol, ldl cholesterol and triglycerides
DE3869806D1 (de) Zusammensetzung gegen leberkrankheiten.
FR2569569B1 (fr) Exerciseur destine notamment au travail du grand ecart.
PT1150703E (pt) Terapia de esclerose multipla com chaperonina 10 e beta-interferao
DE3861932D1 (de) Fadenklappe.

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties